MCLA-117

Date Publication
Jun 12, 2020
Update from the ongoing phase I multinational study of MCLA-117, a bispecific CLEC12A x CD3 T-cell engager, in patients with acute myelogenous leukemia

Poster presented at the virtual edition of the European Hematology Association (EHA) 2020 Annual Congress.

Jul 09, 2019
MCLA-117, a CLEC12AxCD3 bispecific antibody targeting a leukaemic stem cell antigen, induces T cell-mediated AML blast lysis

Pieter Fokko van Loo, Basav N. Hangalapura, Soley Thordardottir, John D. Gibbins, Henrike Veninga, Linda J. A. Hendriks, Arjen Kramer, Rob C. Roovers, Marij Leenders, John de Kruif, Robert P. Doornbos, Andres Sirulnik, Mark Throsby, Ton Logtenberg, Harry Dolstra & Alexander B. H. Bakker. Expert Opinion on Biological Therapy, 19, 721-733 (2019).

Nov 09, 2016
MCLA-117, a CLEC12AXCD3 bispecific IgG targeting a leukemic stem cell antigen, induces T cell mediated AML blast lysis

Pieter Fokko van Loo1, Henrike Veninga1, Harry Dolstra2, and Lex Bakker11Merus NV, Utrecht, Netherlands; 2Radboud University Medical Center and Radboud Institute for Molecular Life Sciences, Nijmegen, Netherlands.

Poster presented at the Society for Immunotherapy of Cancer (SITC) 2016 Annual Meeting, National Harbor, MD, USA.

MCLA-128

Date Publication
May 29, 2020
Clinical activity of MCLA-128 (zenocutuzumab), trastuzumab and vinorelbine in HER2-amplified metastatic breast cancer patients (MBC) who had progressed on anti-HER2 antibody drug conjugates (ADCs)

Poster presented at the American Society of Clinical Oncology (ASCO) 2020 Virtual Annual Meeting

May 29, 2020
Clinical activity of MCLA-128 (zenocutuzumab) in combination with endocrine therapy (ET) in ER+/HER2-low, non-amplified metastatic breast cancer patients with ET-resistant disease who had progressed on a cyclin-dependent kinase (CDK) 4/6 inhibitor

Poster presented at the American Society of Clinical Oncology (ASCO) 2020 Virtual Annual Meeting

May 29, 2020
A phase 2 basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumors

TiP poster presented at the American Society of Clinical Oncology (ASCO) 2020 Virtual Annual Meeting

May 29, 2020
NRG1 fusion-driven cancers: A systematic literature review and meta-analysis.
Viktoriya StalbovskayaErnesto WassermanJon FryzekLauren C Bylsma, and L. Andres Sirulnik.

Journal of Clinical Oncology (2020)

Jan 31, 2020
Population Pharmacokinetics of MCLA-128, a HER2/HER3 Bispecific Monoclonal Antibody, in Patients with Solid Tumors

Aurelia H. M. de Vries Schultink, Kees Bol, Robert P. Doornbos, Anastasia Murat, Ernesto Wasserman, Thomas P. C. Dorlo, Jan H. M. Schellens, Jos H. Beijnen, Alwin D. R. Huitema. Clinical Pharmacokinetics, (2020).

 

Oct 27, 2019
Clinical proof-of-concept for MCLA-128, a bispecific HER2/3 antibody therapy, in NRG1 fusion-positive cancers

Alison M Schram1, Eileen M O’Reilly1, Romel Somwar1, Ryma Benayed1, Sara Shameem1, Thrusha Chauhan1, Jean Torrisi1, Jim Ford2, David Maussang2, Ernesto Wasserman2, Marc Ladanyi1, David M Hyman1, L Andres Sirulnik2, Alexander E Drilon1. 1Memorial Sloan Kettering, NY, USA; 2Merus N.V., Utrecht, Netherlands.

Poster presented at the AACR-NCI-EORTC 2019 Congress, Boston, MA, USA.

Oct 27, 2019
Clinical proof-of-concept for MCLA-128, a bispecific HER2/3 antibody therapy, in NRG1 fusion-positive cancers

Presentation given by Alison M Schram (Memorial Sloan Kettering, NY, USA) at AACR-NCI-EORTC 2019 Congress, Boston, MA, USA.

Sep 29, 2019
A phase 2 basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumors

AM Schram1, A Drilon1, T Macarulla Mercade2, EM O’Reilly1, J Rodon3, B Wolpin4, S-HI Ou5, D-W Kim6, JCH Yang7, YC Lam8, A Varga9, AJ de Langen10, P Witteveen11, V Boni12, G Cerea13, M Duruisseaux14, SV Liu15, E Wasserman16, DM Hyman1, J Tabernero2. 1Memorial Sloan Kettering/Weill Cornell Medical College, NY, USA; 2Vall d’Hebron University Hospital/VHIO, Barcelona, Spain; 3MD Anderson Cancer Center, TX, USA; 4Dana-Farber Cancer Institute, MA, USA; 5University of California Irvine, CA, USA; 6Seoul National University Hospital, Seoul, Republic of Korea ; 7National Taiwan University Cancer Center/Hospital, Taipei, Taiwan; 8National Cancer Centre Singapore, Singapore; 9Gustave Roussy, Villejuif, France; 10Netherlands Cancer Institute, Netherlands, 11UMC Utrecht Cancer Center, Netherlands; 12START Madrid-CIOCC/University Hospital Sanchinarro, Madrid, Spain; 13Niguarda Cancer Center, Ospedale Niguarda/Università degli Studi di Milano, Italy; 14Hôpital Louis Pradel-Hospices Civils de Lyon, France; 15Lombardi Cancer Center Georgetown University, Washington, USA; 16Merus N.V., Utrecht, Netherlands.

Poster presented at the European Society for Medical Oncology (ESMO) 2019 Congress, Barcelona, Spain.

Oct 21, 2018
Phase 1/2 study of single agent MCLA-128, a full length IgG1 bispecific antibody targeting the HER3 pathway: overall safety at the recommended Phase 2 dose (R2PD) and preliminary activity in HER2+ metastatic gastric/gastroesophageal junction cancer (GC/GEJ)

Maria Alsina1, Andrea Varga2, Alessio Amatu3, Jan H.M. Schellens4, Els Witteveen5, Valentina Boni6, Victor Moreno7, Paolo Nuciforo1, Aurelia de Vries Schultink4, Kees Bol8, Afrodite Lourbakos8, Marina Magin Ferrer8, and Ernesto Wasserman8. 1Vall d’Hebron University Hospital, Barcelona, Spain; 2DITEP, Gustave Roussy, Villejuif, France; 3Niguarda Hospital, Milan, Italy; 4Netherlands Cancer Institute, Amsterdam, Netherlands; 5University Medical Center Utrecht, Netherlands; 6START CIOCC, Madrid, Spain; 7START – FJD, Madrid, Spain; 8Merus NV, Utrecht, Netherlands.

Poster presented at the European Society for Medical Oncology (ESMO) 2018 Congress, Munich, Germany.

May 14, 2018
Unbiased combinatorial screening identifies a bispecific IgG1 that potently inhibits HER3 signaling via HER2-guided ligand blockade

Cecile A.W. Geuijen, Camilla De Nardis, David Maussang, Eric Rovers, Tristan Gallenne, Linda J.A. Hendriks, Therese Visser, Roy Nijhuis, Ton Logtenberg, John de Kruif, Piet Gros, and Mark Throsby. Cancer Cell, 33, 922-936 (2018).

MCLA-129

Date Publication
Oct 29, 2019
Preclinical evaluation of MCLA-129: a bispecific antibody targeting c-MET and EGFR

Cecile Geuijen1, Mario di Matteo2,3, Sarah Trusso Cafarello2,3, Tristan Gallenne1, Roy Nijhuis1, Therese Visser1, Willem Bartelink1, Carina Bartelink-Clements1, Vanessa Zondag-van der Zande1, Eric Rovers1, Karin de Cortie1, Linda Kaldenberg-Hendriks1, Berina Eppink1, Rinse Klooster1, John de Kruif1, Massimiliano Mazzone2,3, Mark Throsby1. 1Merus N.V. Utrecht, The Netherlands; 2Laboratory of Tumor Inflammation and Angiogenesis, Center for Cancer Biology, VIB, Leuven, Belgium; 3Laboratory of Tumor Inflammation and Angiogenesis, Center for Cancer Biology, Department of Oncology, KU Leuven, Belgium.

Poster presented at the AACR-NCI-EORTC 2019 Congress, Boston, MA, USA.

MCLA-145

Date Publication
Mar 31, 2019
An unbiased screen identifies a CD137xPD-L1 bispecific IgG1 antibody with unique T cell activation and binding properties

Cecile A. Geuijen1, Paul Tacken1, Rinse Klooster1, Horacio Nastri2, Shaun Stewart2, Jing Zhou2, Steve Wang2, Cheng-Yen Huang2, Arjen Kramer1, Linda Kaldenberg-Hendriks1, John de Kruif1, Renate den Blanken-Smit1, Vanessa Zondag-van de Zande1, Abdul Basmeleh1, Willem Bartelink1, Patrick Mayes2, Gregory Hollis2, Reid Huber2, Mark Throsby11Merus NV, Utrecht, Netherlands; 2Incyte Corporation, Wilmington, DE.

Poster presented at the American Association for Cancer Research (AACR) 2019 Annual Meeting, Atlanta, GA, USA.

Mar 31, 2019
A bispecific Fc-silenced IgG1 antibody (MCLA-145) requires PD-L1 binding to activate CD137

Patrick Mayes1, Paul Tacken2, Steve Wang1, Pieter-Fokko van Loo2, Thomas Condamine1, Hans van der Maaden2, Eric Rovers2, Steef Engels2, Floris Fransen2, Ashwini Kulkarni1, Yao-bin Liu1, Arpita Mondal1, Leslie Hall1, Soyeon Kim3, Marina Martinez3, Shaun O’Brien3, Edmund Moon3, Steven Albelda3, Peggy Scherle1, Gregory Hollis1, Reid Huber1, Mark Throsby2, Cecile A. Geuijen21Incyte Corporation, Wilmington, DE; 2Merus NV, Utrecht, Netherlands; 3University of Pennsylvania, Philadelphia.

Poster presented at the American Association for Cancer Research (AACR) 2019 Annual Meeting, Atlanta, GA, USA.

MCLA-158

Date Publication
Apr 01, 2017
Identification and characterisation of MCLA-158 as an anti-EGFRxLGR5 bispecific antibody that potently inhibits patient-derived CRC organoid growth

Rob C. Roovers1, Bram Herpers2, Mark James3, Berina Eppink1, Carme Cortina3, David Maussang-Detaille1, Ingrid Kolfschoten1, Sylvia F. Boy4, Marc van de Wetering4, Wim de Lau5, Robert Doornbos1, Carina Clements1, Abdul Basmeleh1, Willem Bartelink1, Vanessa Zondag van de Zande1, Kuan Yan2, Lucia Salinaro2, Lex Bakker1, John de Kruif1, Hans Clevers5, Robert Vries4, Eduard Batlle3, Leo Price2 and Mark Throsby1.1Merus NV, Utrecht, Netherlands; 2OcellO BV, Leiden, Netherlands; 3IRB Barcelona, Spain; 4HUB, Utrecht, Netherlands; 5The Hubrecht Institute, Utrecht, Netherlands.

Poster presented at the American Association for Cancer Research (AACR) 2017 Annual Meeting, Washington, DC, USA.

Nov 04, 2015
Generation of Wnt- and mitogenic receptor binding bispecific antibodies to target cancer stem cells

Berina Eppink1, Rob Roovers1, Bram Herpers2, Wim de Lau3, Carina Clements1, Vanessa Zondag van der Zande1, Abdul Basmeleh1, Willem Bartelink1, Marc van de Wetering3,4, Robert Vries3,4, Leo Price2, John de Kruif1, and Mark Throsby11Merus BV Utrecht, Netherlands; 2OcellO BV, Leiden, Netherlands; 3Hubrecht Institute, Utrecht, Netherlands; 4HUB, Utrecht, Netherlands.

Poster presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, MA, USA.

Technology

Date Publication
Jun 12, 2020
T cell engaging bispecific antibodies generated from a novel, large and diverse CD3 panel demonstrate functionality uncoupled from affinity

Poster presented at the virtual edition of the European Hematology Association (EHA) 2020 Annual Congress.

Jun 27, 2017
A new approach for generating bispecific antibodies based on a common light chain format and the stable architecture of human immunoglobulin G1

Camilla De Nardis*, Linda J.A. Hendriks*, Emilie Poirier, Tudor Arvinte, Piet Gros, Alexander B.H. Bakker, and John de Kruif. Journal of Biological Chemistry, 292,  14706-14717 (2017).

Sep 26, 2016
Generation of immuno-modulatory receptor binding bispecific antibodies to modulate tumor immunity

Rinse Klooster, Cecile Geuijen, Renate den Blanken-Smit, Mireille Koenders, Annette Wensink, Eric Rovers, Hans van der Maaden, Steef Engels, Tristan Gallenne, Therese Visser, Carina Bartelink-Clements, Katinka van Zoest, Roy Nijhuis, Abdul Basmeleh, Willem Bartelink, Vanessa Zondag-van der Zande, Arjen Kramer, Linda Kaldenberg, Berina Eppink, Rob Roovers, Paul Tacken, Lex Bakker, Pieter Fokko van Loo, John de Kruif, and Mark Throsby.

Poster presented at the International Congress on Immunotherapies in Cancer (ICIC) 2016 Annual Meeting, New York, NY, USA.

Nov 11, 2013
Complex mixtures of antibodies generated from a single production qualitatively and quantitatively evaluated by native Orbitrap mass spectrometry

Natalie J. Thompson, Linda J.A. Hendriks, John de Kruif, Mark Throsby, and Albert J.R. Heck. mAbs, 6, 197-203 (2013).

Aug 10, 2012
Qualitative and semiquantitative analysis of composite mixtures of antibodies by native mass spectrometry

Sara Rosati, Natalie J. Thompson, Arjan Barendregt, Linda J. A. Hendriks, Alexander B. H. Bakker, John de Kruif, Mark Throsby, Esther van Duijn, and Albert J. R. Heck. Analytical Chemistry, 84, 7227–7232 (2012).

Jun 21, 2010
Generation of stable cell clones expressing mixtures of human antibodies

John de Kruif, Arjen Kramer, Roy Nijhuis, Vanessa van der Zande, Renate den Blanken, Carina Clements, Therese Visser, Rob Keehnen, Marcel den Hartog, Mark Throsby, and Ton Logtenberg. Biotechnology and Bioengineering, 106, 741-750 (2010).

Apr 03, 2009
Human immunoglobulin repertoires against tetanus toxoid contain a large and diverse fraction of high-affinity promiscuous VH genes

John de Kruif, Arjen Kramer, Therèse Visser, Carina Clements, Roy Nijhuis, Freek Cox, Vanessa van der Zande, Renate Smit, Daniel Pinto, Mark Throsby, and Ton Logtenberg. Journal of Molecular Biology, 387, 548-558 (2009).